Compare Eisai Co., Ltd. with Similar Stocks
Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 21.93
2
Poor long term growth as Operating profit has grown by an annual rate -19.80% of over the last 5 years
3
With ROE of 5.71%, it has a very attractive valuation with a 1.39 Price to Book Value
4
Majority shareholders : FIIs
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 1,316,796 Million (Large Cap)
24.00
NA
0.00%
-0.08
5.95%
1.54
Revenue and Profits:
Net Sales:
219,937 Million
(Quarterly Results - Dec 2025)
Net Profit:
17,844 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.36%
0%
4.36%
6 Months
-8.24%
0%
-8.24%
1 Year
11.58%
0%
11.58%
2 Years
-24.58%
0%
-24.58%
3 Years
-32.9%
0%
-32.9%
4 Years
-19.01%
0%
-19.01%
5 Years
-33.54%
0%
-33.54%
Eisai Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.56%
EBIT Growth (5y)
-19.80%
EBIT to Interest (avg)
21.93
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.74
Tax Ratio
21.30%
Dividend Payout Ratio
97.70%
Pledged Shares
0
Institutional Holding
0.08%
ROCE (avg)
6.79%
ROE (avg)
5.99%
Valuation key factors
Factor
Value
P/E Ratio
24
Industry P/E
Price to Book Value
1.39
EV to EBIT
26.57
EV to EBITDA
13.46
EV to Capital Employed
1.43
EV to Sales
1.38
PEG Ratio
2.09
Dividend Yield
0.01%
ROCE (Latest)
5.37%
ROE (Latest)
5.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.08%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
219,937.00
197,362.00
11.44%
Operating Profit (PBDIT) excl Other Income
28,002.00
21,048.00
33.04%
Interest
1,430.00
1,442.00
-0.83%
Exceptional Items
0.00
0.00
Consolidate Net Profit
17,844.00
10,533.00
69.41%
Operating Profit Margin (Excl OI)
81.60%
56.90%
2.47%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 11.44% vs -2.61% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 69.41% vs -31.32% in Sep 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
789,400.00
741,751.00
6.42%
Operating Profit (PBDIT) excl Other Income
89,146.00
86,150.00
3.48%
Interest
2,755.00
1,884.00
46.23%
Exceptional Items
-8,120.00
-3,049.00
-166.32%
Consolidate Net Profit
48,059.00
43,784.00
9.76%
Operating Profit Margin (Excl OI)
62.40%
63.00%
-0.06%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 6.42% vs -0.36% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 9.76% vs -22.96% in Mar 2024
About Eisai Co., Ltd. 
Eisai Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






